Studies have revealed that high tumor burden mutation (TMB) was significantly positively correlated with tumor neoantigens, which can be recognized by infiltrating CD8+ T cells, thus predicting immunotherapy effects (Rizvi et al., 2015; McGranahan et al., 2016; Chan et al., 2019). This evidence concerns the gene CD8A and neoplasm.